Perspective Therapeutics

Company snapshot

We develop game-changing therapies that make an impactful difference for cancer patients and the clinicians who treat them.

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Perspective Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Perspective Therapeutics.

1. Jun 5, 2026 Clinical update

   [212Pb] VMT-α-NET — Phase 1

2. Jun 5, 2026 Clinical update

   [203Pb]VMT-α-NET — Phase 2

3. Jun 5, 2026 Clinical update

   [203Pb]VMT-α-NET — Phase 1

4. May 23, 2026 Clinical update

   [203Pb]Pb-PSV359 — Phase 2

5. May 23, 2026 Clinical update

   [203Pb]VMT01 — Phase 2

View all clinical trial activity →

• What is Perspective Therapeutics?

  Perspective Therapeutics is a pharma organization headquartered in Seattle, USA. It trades on NYSE under ticker CATX. Primary therapeutic focus areas include Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors Unresectable, Melanoma (Skin), Recur

• Is Perspective Therapeutics publicly traded?

  Yes. Perspective Therapeutics is listed with ticker CATX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Perspective Therapeutics develop or market?

  We link 1 drug profile(s) where Perspective Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/perspective-therapeutics#company-drugs.

• What are the latest developments for Perspective Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Perspective Therapeutics focus on?

  Perspective Therapeutics focuses on Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors Unresectable based on our analysis of their pipeline programs and drug development activities.